2022
A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy
Ibrahim EY, Munshani S, Domenicano I, Rodwin R, Nowak RJ, Pusztai L, Lustberg M, Ehrlich BE. A preliminary, prospective study of peripheral neuropathy and cognitive function in patients with breast cancer during taxane therapy. PLOS ONE 2022, 17: e0275648. PMID: 36206298, PMCID: PMC9543876, DOI: 10.1371/journal.pone.0275648.Peer-Reviewed Original ResearchConceptsNeurological side effectsSide effectsBreast cancerTaxane exposureProgressive neurological changesTaxane-based chemotherapyNon-interventional studyWeeks of treatmentEnd of treatmentIrreversible side effectsCourse of treatmentQuality of lifeTaxane therapyPeripheral neuropathyProspective studyPeripheral bloodBlood levelsCancer survivalNeuronal viabilityNeurological changesEffective treatmentChemotherapyCognitive impairmentPatientsPotential protein biomarkersRisk-adapted modulation through de-intensification of cancer treatments: an ESMO classification
Trapani D, Franzoi M, Burstein H, Carey L, Delaloge S, Harbeck N, Hayes D, Kalinsky K, Pusztai L, Regan M, Sestak I, Spanic T, Sparano J, Jezdic S, Cherny N, Curigliano G, Andre F. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Annals Of Oncology 2022, 33: 702-712. PMID: 35550723, DOI: 10.1016/j.annonc.2022.03.273.Peer-Reviewed Original ResearchConceptsNon-inferiority clinical trialClinical trialsESMO classificationCancer treatmentPrecision Medicine Working GroupSingle-arm studyHealth system burdenOngoing clinical trialsShorter treatment durationLevel of evidenceEvidence-based criteriaQuality of lifePublic health expertsMedicine Working GroupStandard regimensCohort investigationWorking GroupCumulative doseTreatment modalitiesTreatment modulationPatient representativesTreatment durationIntermittent scheduleFinancial toxicityEvidence of reduction
2020
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
Loi S, McArthur H, Harbeck N, Pusztai L, Delaloge S, Letrent K, Chen T, Li B, Tatsuoka K, Zardavas D, Curigliano G. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL. Journal Of Clinical Oncology 2020, 38: tps604-tps604. DOI: 10.1200/jco.2020.38.15_suppl.tps604.Peer-Reviewed Original ResearchAdjuvant endocrine therapyPathologic complete responsePrimary breast cancerEndocrine therapyNeoadjuvant chemotherapyBreast cancerNeoadjuvant phaseER expressionGlobal phase 3 studyDeath ligand 1 (PD-L1) expressionLong-term clinical outcomesAdequate organ functionDeath-1 (PD-1) inhibitionLow ER expressionAxillary nodal statusDisease-free survivalEvent-free survivalLigand 1 expressionPhase III trialsResidual cancer burdenPhase 3 studyOverall response rateRisk of relapseValid surrogate endpointQuality of life
2014
Impact of Financial Burden of Cancer on Survivors' Quality of Life
Fenn KM, Evans SB, McCorkle R, DiGiovanna MP, Pusztai L, Sanft T, Hofstatter EW, Killelea BK, Knobf MT, Lannin DR, Abu-Khalaf M, Horowitz NR, Chagpar AB. Impact of Financial Burden of Cancer on Survivors' Quality of Life. JCO Oncology Practice 2014, 10: 332-338. PMID: 24865220, DOI: 10.1200/jop.2013.001322.Peer-Reviewed Original ResearchConceptsQuality of lifeNational Health Interview SurveyStrong independent predictorCancer care costsIndependent predictorsCancer survivorsCare costsHealth Interview SurveyFinancial burdenPopulation-based sampleMultivariable regression modelsMultivariable analysisSurvivors' qualityPatientsBivariate analysisCancerSignificant covariatesMental healthPhysical healthInterview SurveyEmotional healthFinancial problemsSurvivorsPoor qualityRegression models